An unexpected battle with peripartum cardiomyopathy: a case report.

IF 1.6 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
Future cardiology Pub Date : 2025-03-01 Epub Date: 2025-02-28 DOI:10.1080/14796678.2025.2472590
Bryan Tornabene, David Waldron, Hannah Short, Nicholas Duca
{"title":"An unexpected battle with peripartum cardiomyopathy: a case report.","authors":"Bryan Tornabene, David Waldron, Hannah Short, Nicholas Duca","doi":"10.1080/14796678.2025.2472590","DOIUrl":null,"url":null,"abstract":"<p><p>Peripartum cardiomyopathy (PPCM) is a rare cardiomyopathy marked by systolic dysfunction that presents in late pregnancy or the early postpartum period with an ejection fraction (EF) of less than 45%. Diagnosing PPCM often presents a diagnostic dilemma due to its nonspecific clinical presentation, which usually resembles physiological changes of pregnancy or peripartum pulmonary embolism. Echocardiography is frequently used as a diagnostic modality of choice with management following the GDMT guidelines and delivery. This case presents a 23-year-old patient with a delayed diagnosis of PPCM, followed by a discussion of goal-directed medical therapy (GDMT) and the benefits of early diagnosis and treatment. Common pitfalls in diagnosing PPCM are introduced to encourage clinicians to consider PPCM during late pregnancy. Currently, a new clinical trial is underway investigating the efficacy of dopamine agonists in conjunction with GDMT for treatment of peripartum cardiomyopathy.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"223-227"},"PeriodicalIF":1.6000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11901409/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/14796678.2025.2472590","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/28 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Peripartum cardiomyopathy (PPCM) is a rare cardiomyopathy marked by systolic dysfunction that presents in late pregnancy or the early postpartum period with an ejection fraction (EF) of less than 45%. Diagnosing PPCM often presents a diagnostic dilemma due to its nonspecific clinical presentation, which usually resembles physiological changes of pregnancy or peripartum pulmonary embolism. Echocardiography is frequently used as a diagnostic modality of choice with management following the GDMT guidelines and delivery. This case presents a 23-year-old patient with a delayed diagnosis of PPCM, followed by a discussion of goal-directed medical therapy (GDMT) and the benefits of early diagnosis and treatment. Common pitfalls in diagnosing PPCM are introduced to encourage clinicians to consider PPCM during late pregnancy. Currently, a new clinical trial is underway investigating the efficacy of dopamine agonists in conjunction with GDMT for treatment of peripartum cardiomyopathy.

意外的围产期心肌病之战:1例报告。
围产期心肌病(PPCM)是一种罕见的心肌病,以收缩功能障碍为特征,出现在妊娠晚期或产后早期,射血分数(EF)小于45%。诊断PPCM往往是一个诊断困境,由于其非特异性的临床表现,通常类似于怀孕或围产期肺栓塞的生理变化。超声心动图经常被用作选择的诊断方式与管理遵循GDMT指南和交付。本病例介绍了一位23岁的PPCM延迟诊断患者,随后讨论了目标导向的药物治疗(GDMT)和早期诊断和治疗的益处。介绍了诊断PPCM的常见缺陷,以鼓励临床医生在妊娠后期考虑PPCM。目前,一项新的临床试验正在研究多巴胺激动剂联合GDMT治疗围产期心肌病的疗效。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Future cardiology
Future cardiology CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
2.80
自引率
5.90%
发文量
87
期刊介绍: Research advances have contributed to improved outcomes across all specialties, but the rate of advancement in cardiology has been exceptional. Concurrently, the population of patients with cardiac conditions continues to grow and greater public awareness has increased patients" expectations of new drugs and devices. Future Cardiology (ISSN 1479-6678) reflects this new era of cardiology and highlights the new molecular approach to advancing cardiovascular therapy. Coverage will also reflect the major technological advances in bioengineering in cardiology in terms of advanced and robust devices, miniaturization, imaging, system modeling and information management issues.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信